|
1
|
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).
|
Eur Heart J
|
2015
|
5.15
|
|
2
|
Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial.
|
JAMA
|
2006
|
4.18
|
|
3
|
Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry.
|
EuroIntervention
|
2015
|
4.00
|
|
4
|
Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents.
|
N Engl J Med
|
2007
|
3.84
|
|
5
|
Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial.
|
JAMA
|
2006
|
3.78
|
|
6
|
Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.
|
N Engl J Med
|
2005
|
3.75
|
|
7
|
Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial.
|
JAMA
|
2005
|
3.67
|
|
8
|
Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial.
|
JAMA
|
2003
|
3.52
|
|
9
|
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
|
J Am Coll Cardiol
|
2009
|
3.15
|
|
10
|
Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial.
|
Lancet
|
2012
|
3.12
|
|
11
|
A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
|
N Engl J Med
|
2004
|
3.07
|
|
12
|
A randomized trial of coronary stenting versus balloon angioplasty as a rescue intervention after failed thrombolysis in patients with acute myocardial infarction.
|
J Am Coll Cardiol
|
2004
|
2.67
|
|
13
|
Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial.
|
J Am Coll Cardiol
|
2003
|
2.53
|
|
14
|
Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial.
|
JAMA
|
2005
|
2.53
|
|
15
|
A meta-analysis of 17 randomized trials of a percutaneous coronary intervention-based strategy in patients with stable coronary artery disease.
|
J Am Coll Cardiol
|
2008
|
2.49
|
|
16
|
Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period.
|
Eur Heart J
|
2009
|
2.47
|
|
17
|
Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment.
|
Thromb Haemost
|
2008
|
2.46
|
|
18
|
Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point.
|
J Am Coll Cardiol
|
2008
|
2.38
|
|
19
|
Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention.
|
Circulation
|
2012
|
2.32
|
|
20
|
Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents.
|
Circulation
|
2006
|
2.18
|
|
21
|
Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial.
|
JAMA
|
2004
|
2.17
|
|
22
|
Therapy-dependent influence of time-to-treatment interval on myocardial salvage in patients with acute myocardial infarction treated with coronary artery stenting or thrombolysis.
|
Circulation
|
2003
|
1.97
|
|
23
|
Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention.
|
Eur Heart J
|
2009
|
1.92
|
|
24
|
Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial.
|
Eur Heart J
|
2009
|
1.81
|
|
25
|
A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease.
|
J Am Coll Cardiol
|
2007
|
1.81
|
|
26
|
Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction.
|
Eur Heart J
|
2007
|
1.76
|
|
27
|
Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement.
|
Am Heart J
|
2004
|
1.73
|
|
28
|
Prognostic value of sensitive troponin T in patients with stable and unstable angina and undetectable conventional troponin.
|
Am Heart J
|
2011
|
1.70
|
|
29
|
Evolution of left ventricular ejection fraction and its relationship to infarct size after acute myocardial infarction.
|
J Am Coll Cardiol
|
2007
|
1.69
|
|
30
|
Saphenous vein graft intervention.
|
JACC Cardiovasc Interv
|
2011
|
1.69
|
|
31
|
Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial.
|
Eur Heart J
|
2005
|
1.68
|
|
32
|
Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer.
|
JACC Cardiovasc Interv
|
2009
|
1.67
|
|
33
|
Prognostic value of uric acid in patients with acute coronary syndromes.
|
Am J Cardiol
|
2012
|
1.67
|
|
34
|
No association of chromosome 9p21.3 variation with clinical and angiographic outcomes after placement of drug-eluting stents.
|
JACC Cardiovasc Interv
|
2009
|
1.67
|
|
35
|
Myocardial perfusion grade, myocardial salvage indices and long-term mortality in patients with acute myocardial infarction and full restoration of epicardial blood flow after primary percutaneous coronary intervention.
|
Rev Esp Cardiol
|
2010
|
1.65
|
|
36
|
CD14 gene -159C/T polymorphism is not associated with coronary artery disease and myocardial infarction.
|
Am Heart J
|
2002
|
1.59
|
|
37
|
Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials.
|
JAMA
|
2005
|
1.57
|
|
38
|
ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention.
|
Eur Heart J
|
2010
|
1.56
|
|
39
|
Age-dependent effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions.
|
Circulation
|
2006
|
1.55
|
|
40
|
Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial.
|
Eur Heart J
|
2010
|
1.55
|
|
41
|
Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation.
|
J Am Coll Cardiol
|
2013
|
1.54
|
|
42
|
Vessel size and outcome after coronary drug-eluting stent placement: results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents.
|
J Am Coll Cardiol
|
2006
|
1.54
|
|
43
|
Culotte stenting technique in coronary bifurcation disease: angiographic follow-up using dedicated quantitative coronary angiographic analysis and 12-month clinical outcomes.
|
Eur Heart J
|
2008
|
1.54
|
|
44
|
Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy.
|
J Am Coll Cardiol
|
2012
|
1.49
|
|
45
|
2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation.
|
Rev Esp Cardiol (Engl Ed)
|
2015
|
1.49
|
|
46
|
Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting.
|
Am Heart J
|
2005
|
1.48
|
|
47
|
One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial.
|
Eur Heart J
|
2007
|
1.47
|
|
48
|
One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial.
|
EuroIntervention
|
2013
|
1.47
|
|
49
|
Prognostic value of late gadolinium enhancement in cardiovascular magnetic resonance imaging after acute ST-elevation myocardial infarction in comparison with single-photon emission tomography using Tc99m-Sestamibi.
|
Eur Heart J Cardiovasc Imaging
|
2013
|
1.47
|
|
50
|
Association of a genetic variant of endothelial nitric oxide synthase with the 1 year clinical outcome after coronary stent placement.
|
Eur Heart J
|
2003
|
1.46
|
|
51
|
Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events.
|
Am Heart J
|
2010
|
1.46
|
|
52
|
Drug-eluting stents versus bare-metal stents in diabetic patients with ST-segment elevation acute myocardial infarction: a pooled analysis of individual patient data from seven randomized trials.
|
Rev Esp Cardiol
|
2009
|
1.45
|
|
53
|
Angiographic outcomes with biodegradable polymer and permanent polymer drug-eluting stents.
|
Catheter Cardiovasc Interv
|
2011
|
1.44
|
|
54
|
Thoracic radiotherapy in patients with lymphoma and restenosis after coronary stent placement.
|
Catheter Cardiovasc Interv
|
2007
|
1.43
|
|
55
|
Five-year outcome of patients with acute myocardial infarction enrolled in a randomised trial assessing the value of abciximab during coronary artery stenting.
|
Eur Heart J
|
2004
|
1.43
|
|
56
|
Randomised, double-blind trial on the value of tapered discontinuation of clopidogrel maintenance therapy after drug-eluting stent implantation. Intracoronary Stenting and Antithrombotic Regimen: CAUTION in Discontinuing Clopidogrel Therapy--ISAR-CAUTION.
|
Thromb Haemost
|
2014
|
1.42
|
|
57
|
Platelets contribute to postnatal occlusion of the ductus arteriosus.
|
Nat Med
|
2009
|
1.41
|
|
58
|
Angiotensin I-converting enzyme (ACE) inhibitors and restenosis after coronary artery stenting in patients with the DD genotype of the ACE gene.
|
J Am Coll Cardiol
|
2003
|
1.41
|
|
59
|
5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction.
|
J Am Coll Cardiol
|
2010
|
1.39
|
|
60
|
Comparisons of the uptake and in-hospital outcomes associated with second-generation drug-eluting stents between men and women: results from the CathPCI Registry.
|
Coron Artery Dis
|
2016
|
1.39
|
|
61
|
Patterns of presentation and outcomes of patients with acute coronary syndromes.
|
Cardiology
|
2009
|
1.39
|
|
62
|
[Treatment of Paclitaxel-eluting stent restenosis with sirolimus-eluting stent implantation: angiographic and clinical outcomes].
|
Rev Esp Cardiol
|
2008
|
1.38
|
|
63
|
2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents.
|
J Am Coll Cardiol
|
2010
|
1.38
|
|
64
|
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
|
N Engl J Med
|
2008
|
1.37
|
|
65
|
No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
|
Eur Heart J
|
2011
|
1.29
|
|
66
|
Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction.
|
Circ Cardiovasc Interv
|
2010
|
1.24
|
|
67
|
Assessment of coronary flow reserve: comparison between contrast-enhanced magnetic resonance imaging and positron emission tomography.
|
J Am Coll Cardiol
|
2002
|
1.22
|
|
68
|
Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.
|
N Engl J Med
|
2011
|
1.20
|
|
69
|
Rationale and design of a randomised clinical trial comparing vascular closure device and manual compression to achieve haemostasis after diagnostic coronary angiography: the Instrumental Sealing of ARterial puncture site - CLOSURE device versus manual compression (ISAR-CLOSURE) trial.
|
EuroIntervention
|
2014
|
1.16
|
|
70
|
Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial.
|
Lancet
|
2002
|
1.14
|
|
71
|
Comparison of C-reactive protein levels before and after coronary stenting and restenosis among patients treated with sirolimus-eluting versus bare metal stents.
|
Am J Cardiol
|
2005
|
1.11
|
|
72
|
Collagen plug vascular closure devices and reduced risk of bleeding with bivalirudin versus heparin plus abciximab in patients undergoing percutaneous coronary intervention for non st-segment elevation myocardial infarction.
|
J Interv Cardiol
|
2013
|
1.10
|
|
73
|
Prognostic value of myocardial salvage achieved by reperfusion therapy in patients with acute myocardial infarction.
|
J Nucl Med
|
2004
|
1.09
|
|
74
|
Three-dimensional transoesophageal echocardiography for the assessment of clip attachment to the leaflets in percutaneous edge-to-edge repair of the mitral valve.
|
EuroIntervention
|
2013
|
1.09
|
|
75
|
A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents.
|
Eur Heart J
|
2009
|
1.08
|
|
76
|
Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease.
|
J Am Coll Cardiol
|
2006
|
1.07
|
|
77
|
Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial.
|
J Am Coll Cardiol
|
2011
|
1.07
|
|
78
|
Five-year clinical outcomes of sirolimus-eluting versus paclitaxel-eluting stents in high-risk patients.
|
Catheter Cardiovasc Interv
|
2011
|
1.07
|
|
79
|
Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial.
|
Circulation
|
2004
|
1.06
|
|
80
|
Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective.
|
EuroIntervention
|
2015
|
1.04
|
|
81
|
Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial.
|
Circ Cardiovasc Interv
|
2010
|
1.04
|
|
82
|
Prognostic value of N-terminal pro-brain natriuretic peptide in patients with chronic stable angina.
|
Circulation
|
2005
|
1.00
|
|
83
|
Impact of perfusion restoration at epicardial and tissue levels on markers of myocardial necrosis and clinical outcome of patients with acute myocardial infarction.
|
EuroIntervention
|
2011
|
1.00
|
|
84
|
Predictive value of basal C-reactive protein levels for myocardial salvage in patients with acute myocardial infarction is dependent on the type of reperfusion treatment.
|
Eur Heart J
|
2003
|
0.95
|
|
85
|
Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial.
|
Circulation
|
2011
|
0.95
|
|
86
|
Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era.
|
Am Heart J
|
2007
|
0.94
|
|
87
|
Plasma levels of N-terminal pro-brain natriuretic peptide in patients with coronary artery disease and relation to clinical presentation, angiographic severity, and left ventricular ejection fraction.
|
Am J Cardiol
|
2005
|
0.94
|
|
88
|
Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials.
|
J Am Coll Cardiol
|
2006
|
0.94
|
|
89
|
Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease.
|
Am Heart J
|
2007
|
0.93
|
|
90
|
Thrombolysis in myocardial infarction myocardial perfusion grade in angiography correlates with myocardial salvage in patients with acute myocardial infarction treated with stenting or thrombolysis.
|
J Am Coll Cardiol
|
2003
|
0.93
|
|
91
|
Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting.
|
Am J Med
|
2003
|
0.92
|
|
92
|
Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating.
|
Eur Heart J
|
2005
|
0.91
|
|
93
|
Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial.
|
Catheter Cardiovasc Interv
|
2012
|
0.91
|
|
94
|
Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting.
|
Thromb Haemost
|
2009
|
0.91
|
|
95
|
Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions. Pooled analysis of four ISAR trials.
|
Thromb Haemost
|
2007
|
0.91
|
|
96
|
Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention.
|
Eur Heart J
|
2009
|
0.91
|
|
97
|
Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study.
|
Am Heart J
|
2009
|
0.90
|
|
98
|
Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials.
|
Clin Res Cardiol
|
2010
|
0.90
|
|
99
|
High-sensitivity troponin T level and angiographic severity of coronary artery disease.
|
Am J Cardiol
|
2011
|
0.89
|
|
100
|
ABO locus O1 allele and risk of myocardial infarction.
|
Blood Coagul Fibrinolysis
|
2004
|
0.89
|
|
101
|
A randomized evaluation of the effects of glucose-insulin-potassium infusion on myocardial salvage in patients with acute myocardial infarction treated with reperfusion therapy.
|
Am Heart J
|
2004
|
0.89
|
|
102
|
Choice of contrast medium in patients with impaired renal function undergoing percutaneous coronary intervention.
|
Circ Cardiovasc Interv
|
2009
|
0.88
|
|
103
|
A double-blind, randomized study on prevention and existence of a rebound phenomenon of platelets after cessation of clopidogrel treatment.
|
J Am Coll Cardiol
|
2010
|
0.88
|
|
104
|
A randomized trial comparing myocardial salvage achieved by coronary stenting versus balloon angioplasty in patients with acute myocardial infarction considered ineligible for reperfusion therapy.
|
J Am Coll Cardiol
|
2004
|
0.88
|
|
105
|
Tissue factor promotor polymorphism -603 A/G is associated with myocardial infarction.
|
Atherosclerosis
|
2004
|
0.88
|
|
106
|
Early resolution of ST-segment elevation correlates with myocardial salvage assessed by Tc-99m sestamibi scintigraphy in patients with acute myocardial infarction after mechanical or thrombolytic reperfusion therapy.
|
Circulation
|
2002
|
0.88
|
|
107
|
Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization.
|
J Am Coll Cardiol
|
2004
|
0.87
|
|
108
|
Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms, plasma homocysteine, folate, and vitamin B12 levels and the extent of coronary artery disease.
|
Am J Cardiol
|
2004
|
0.87
|
|
109
|
Prognostic significance of epicardial blood flow before and after percutaneous coronary intervention in patients with acute coronary syndromes.
|
J Am Coll Cardiol
|
2008
|
0.85
|
|
110
|
Relationship between residual blood flow in the infarct-related artery and scintigraphic infarct size, myocardial salvage, and functional recovery in patients with acute myocardial infarction.
|
J Nucl Med
|
2005
|
0.85
|
|
111
|
Peak cardiac troponin-T level, scintigraphic myocardial infarct size and one-year prognosis in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction.
|
Am J Cardiol
|
2010
|
0.85
|
|
112
|
Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials.
|
Circ Cardiovasc Interv
|
2011
|
0.85
|
|
113
|
4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting.
|
Am Heart J
|
2003
|
0.85
|
|
114
|
Randomized comparison of biolimus-eluting stents with biodegradable polymer versus everolimus-eluting stents with permanent polymer coatings assessed by optical coherence tomography.
|
Int J Cardiovasc Imaging
|
2014
|
0.84
|
|
115
|
Impact of myocardial salvage assessed by (99m)Tc-sestamibi scintigraphy on cardiac autonomic function in patients undergoing mechanical reperfusion therapy for acute myocardial infarction.
|
JACC Cardiovasc Imaging
|
2009
|
0.84
|
|
116
|
Statin treatment following coronary artery stenting and one-year survival.
|
J Am Coll Cardiol
|
2002
|
0.84
|
|
117
|
Influence of stent surface topography on the outcomes of patients undergoing coronary stenting: a randomized double-blind controlled trial.
|
Catheter Cardiovasc Interv
|
2005
|
0.84
|
|
118
|
Comparative efficacy of 2 zotarolimus-eluting stent generations: resolute versus endeavor stents in patients with coronary artery disease.
|
Am Heart J
|
2012
|
0.84
|
|
119
|
Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment.
|
Thromb Haemost
|
2010
|
0.83
|
|
120
|
Circulating homocysteine levels in patients with type 2 diabetes mellitus.
|
Nutr Metab Cardiovasc Dis
|
2006
|
0.83
|
|
121
|
Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment.
|
Clin Res Cardiol
|
2007
|
0.83
|
|
122
|
Homocysteine status and polymorphisms of methylenetetrahydrofolate reductase are not associated with restenosis after stenting in coronary arteries.
|
Arterioscler Thromb Vasc Biol
|
2003
|
0.83
|
|
123
|
Comparison of prasugrel and bivalirudin vs clopidogrel and heparin in patients with ST-segment elevation myocardial infarction: Design and rationale of the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 trial.
|
Clin Cardiol
|
2014
|
0.83
|
|
124
|
Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force.
|
Europace
|
2014
|
0.83
|
|
125
|
[2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation].
|
Kardiol Pol
|
2015
|
0.82
|
|
126
|
No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting.
|
Circ Cardiovasc Interv
|
2012
|
0.82
|
|
127
|
Coronary revascularization in patients with renal insufficiency: restenosis rate and cardiovascular outcomes.
|
Am J Kidney Dis
|
2004
|
0.82
|
|
128
|
Impact of body mass index on clinical outcome in patients with acute coronary syndromes treated with percutaneous coronary intervention.
|
Heart Vessels
|
2010
|
0.81
|
|
129
|
Predictive factors for early cardiac events and angiographic restenosis after coronary stent placement in small coronary arteries.
|
J Am Coll Cardiol
|
2002
|
0.81
|
|
130
|
A randomized, double-blind, placebo-controlled trial on restenosis prevention by the receptor tyrosine kinase inhibitor imatinib.
|
J Am Coll Cardiol
|
2005
|
0.81
|
|
131
|
Clopidogrel therapy in patients undergoing coronary stenting: value of a high-loading-dose regimen.
|
Catheter Cardiovasc Interv
|
2002
|
0.81
|
|
132
|
Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents.
|
Am Heart J
|
2010
|
0.81
|
|
133
|
A prospective cohort study of prognostic power of N-terminal probrain natriuretic peptide in patients with non-ST segment elevation acute coronary syndromes.
|
Clin Res Cardiol
|
2006
|
0.81
|
|
134
|
Impact of lesion complexity on the capacity of a trial to detect differences in stent performance: results from the ISAR-STEREO trial.
|
Am Heart J
|
2003
|
0.81
|
|
135
|
Gender differences in therapeutic recommendation after diagnostic coronary angiography: insights from the Coronary Angiography and PCI Registry of the German Society of Cardiology.
|
Clin Res Cardiol
|
2015
|
0.80
|
|
136
|
Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization: the TiNOX trial.
|
Circulation
|
2005
|
0.80
|
|
137
|
ACS and STEMI treatment: gender-related issues.
|
EuroIntervention
|
2012
|
0.80
|
|
138
|
Second-versus first-generation "Limus"-eluting stents in diabetic patients with coronary artery disease: a randomized comparison in setting of ISAR-TEST-4 trial.
|
Catheter Cardiovasc Interv
|
2013
|
0.80
|
|
139
|
N-terminal probrain natriuretic peptide and C-reactive protein in stable coronary heart disease.
|
Am J Med
|
2006
|
0.80
|
|
140
|
Percutaneous edge-to-edge repair of the mitral valve in patients with degenerative versus functional mitral regurgitation.
|
Catheter Cardiovasc Interv
|
2014
|
0.80
|
|
141
|
One-year clinical outcomes with abciximab in acute myocardial infarction: results of the BRAVE-3 randomized trial.
|
Clin Res Cardiol
|
2010
|
0.80
|
|
142
|
One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel.
|
Eur Heart J
|
2005
|
0.79
|
|
143
|
Does addition of estradiol improve the efficacy of a rapamycin-eluting stent? Results of the ISAR-PEACE randomized trial.
|
J Am Coll Cardiol
|
2007
|
0.79
|
|
144
|
Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
|
Circ Cardiovasc Interv
|
2012
|
0.79
|
|
145
|
Total leucocyte count, but not C-reactive protein, predicts 1-year mortality in patients with acute coronary syndromes treated with percutaneous coronary intervention.
|
Clin Sci (Lond)
|
2009
|
0.79
|
|
146
|
Apolipoprotein E gene polymorphisms and thrombosis and restenosis after coronary artery stenting.
|
J Lipid Res
|
2004
|
0.79
|
|
147
|
Ability of mechanical reperfusion to salvage myocardium in patients with acute myocardial infarction presenting beyond 12 hours after onset of symptoms.
|
Am Heart J
|
2006
|
0.79
|
|
148
|
Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; evidence in support of drug resistance: insights from the ISAR-DESIRE and ISAR-DESIRE 2 trials.
|
EuroIntervention
|
2013
|
0.79
|
|
149
|
Transcatheter treatment of severe tricuspid regurgitation using the edge-to-edge repair technique.
|
EuroIntervention
|
2017
|
0.79
|
|
150
|
A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
|
Thromb Haemost
|
2016
|
0.78
|
|
151
|
Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel.
|
Eur Heart J
|
2010
|
0.78
|
|
152
|
A prospective cohort study of predictive value of homocysteine in patients with type 2 diabetes and coronary artery disease.
|
Clin Chim Acta
|
2006
|
0.78
|
|
153
|
ST-segment resolution after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction.
|
Cardiol J
|
2012
|
0.78
|
|
154
|
Comparative analysis of stent placement versus balloon angioplasty in small coronary arteries with long narrowings (the Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries [ISAR-SMART] Trial).
|
Am J Cardiol
|
2002
|
0.78
|
|
155
|
Bleeding after percutaneous coronary intervention with Bivalirudin or unfractionated Heparin and one-year mortality.
|
Am J Cardiol
|
2009
|
0.78
|
|
156
|
The occupational effects of interventional cardiology: results from the WIN for Safety survey.
|
EuroIntervention
|
2012
|
0.78
|
|
157
|
Gender differences in cardiovascular therapy: focus on antithrombotic therapy and percutaneous coronary intervention.
|
Drugs
|
2013
|
0.78
|
|
158
|
Prognostic value of minimal blood flow restoration in patients with acute myocardial infarction after reperfusion therapy.
|
Clin Res Cardiol
|
2009
|
0.78
|
|
159
|
Randomized trial of rapamycin- and paclitaxel-eluting stents with identical biodegradable polymeric coating and design.
|
Eur Heart J
|
2007
|
0.78
|
|
160
|
Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score.
|
EuroIntervention
|
2017
|
0.78
|
|
161
|
Accuracy of N-terminal probrain natriuretic peptide to predict mortality or detect acute ischemia in patients with coronary artery disease.
|
Cardiology
|
2007
|
0.78
|
|
162
|
Lack of association between circulating levels of plasma oxidized low-density lipoproteins and clinical outcome after coronary stenting.
|
Am Heart J
|
2005
|
0.77
|
|
163
|
Serum potassium levels on admission and infarct size in patients with acute myocardial infarction.
|
Clin Chim Acta
|
2009
|
0.77
|
|
164
|
Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors.
|
Thromb Haemost
|
2010
|
0.77
|
|
165
|
N-terminal pro-brain natriuretic peptide on admission in patients with acute myocardial infarction and correlation with scintigraphic infarct size, efficacy of reperfusion, and prognosis.
|
Am J Cardiol
|
2006
|
0.77
|
|
166
|
Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function.
|
Cardiology
|
2008
|
0.77
|
|
167
|
[Intracoronary Stenting and Angiographic Results Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) Trial].
|
Vestn Rentgenol Radiol
|
2012
|
0.77
|
|
168
|
Effects of verbal suggestion on coronary arteries: results of a randomized controlled experimental investigation during coronary angiography.
|
Am Heart J
|
2011
|
0.77
|
|
169
|
Prognostic value of kidney function in patients with ST-elevation and non-ST-elevation acute myocardial infarction treated with percutaneous coronary intervention.
|
Am J Kidney Dis
|
2009
|
0.77
|
|
170
|
12 months outcomes after Bioresorbable Vascular Scaffold implantation in Patients with Acute Coronary Syndromes. Data from the European Multicentre GHOST-EU Extended Registry.
|
EuroIntervention
|
2017
|
0.77
|
|
171
|
Sensitive troponin and N-terminal probrain natriuretic peptide in stable angina.
|
Eur J Clin Invest
|
2011
|
0.77
|
|
172
|
Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry.
|
EuroIntervention
|
2016
|
0.77
|
|
173
|
Dangerous liaison: successful percutaneous edge-to-edge mitral valve repair in patients with end-stage systolic heart failure can cause left ventricular thrombus formation.
|
EuroIntervention
|
2014
|
0.77
|
|
174
|
Long-term outcome of patients with severe biventricular heart failure and severe mitral regurgitation after percutaneous edge-to-edge mitral valve repair.
|
J Interv Cardiol
|
2015
|
0.76
|
|
175
|
[2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)].
|
G Ital Cardiol (Rome)
|
2016
|
0.76
|
|
176
|
Long-term risk of adverse outcomes and new malignancies in patients treated with oral sirolimus for prevention of restenosis.
|
JACC Cardiovasc Interv
|
2009
|
0.76
|
|
177
|
Abciximab and angiographic restenosis after coronary stent placement. Analysis of the angiographic substudy of ISAR-REACT--a double-blind, placebo-controlled, randomized trial evaluating abciximab in patients undergoing elective percutaneous coronary interventions after pretreatment with a high loading dose of clopidogrel.
|
Am Heart J
|
2006
|
0.76
|
|
178
|
Mechanical reperfusion and long-term mortality in patients with acute myocardial infarction presenting 12 to 48 hours from onset of symptoms.
|
JAMA
|
2009
|
0.76
|
|
179
|
Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial.
|
Clin Res Cardiol
|
2011
|
0.76
|
|
180
|
Statin effect on thrombin inhibitor effectiveness during percutaneous coronary intervention: a post-hoc analysis from the ISAR-REACT 3 trial.
|
Clin Res Cardiol
|
2011
|
0.76
|
|
181
|
Characterization of patients with bleeding complications who are at increased risk of death after percutaneous coronary intervention.
|
Heart Vessels
|
2010
|
0.75
|
|
182
|
In vitro evaluation of implantation depth in valve-in-valve using different transcatheter heart valves.
|
EuroIntervention
|
2016
|
0.75
|
|
183
|
Iron status and clinical outcome in patients with coronary artery disease after coronary stenting.
|
Nutr Metab Cardiovasc Dis
|
2005
|
0.75
|
|
184
|
Reply: Duration of Triple Therapy: A Clinical Question Yet to Be Answered.
|
J Am Coll Cardiol
|
2015
|
0.75
|
|
185
|
Reply: Duration of Triple Therapy in Patients Requiring Oral Anticoagulation After Drug-Eluting Stent Implantation.
|
J Am Coll Cardiol
|
2015
|
0.75
|
|
186
|
Left main coronary artery compression in a young woman with Eisenmenger syndrome.
|
Heart Asia
|
2011
|
0.75
|
|
187
|
Transcatheter Treatment of Severe Tricuspid Regurgitation Using the Edge-to-Edge Repair Technique in the Presence and Absence of Pacemaker Leads.
|
JACC Cardiovasc Interv
|
2017
|
0.75
|
|
188
|
Myocardial salvage after reduced-dose thrombolysis combined with glycoprotein IIb/IIIa blockade versus thrombolysis alone in patients with acute myocardial infarction.
|
J Thromb Thrombolysis
|
2004
|
0.75
|
|
189
|
Effect of abciximab on clinical and angiographic restenosis in patients with non-ST-segment elevation acute coronary syndromes.
|
Am J Cardiol
|
2008
|
0.75
|
|
190
|
Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents.
|
Thromb Haemost
|
2017
|
0.75
|
|
191
|
Impact of acute myocardial infarct location on myocardial salvage after stenting or thrombolysis (results from the STOPAMI 1 and 2 trials): Stent versus Thrombolysis for Occluded coronary arteries in Patients with Acute Myocardial Infarction.
|
Am J Cardiol
|
2003
|
0.75
|
|
192
|
Aortic regurgitation with second versus third-generation balloon-expandable prostheses in patients undergoing transcatheter aortic valve implantation.
|
EuroIntervention
|
2015
|
0.75
|
|
193
|
Plasminogen activator inhibitor-1 4G/5G polymorphism and efficacy of reperfusion therapy in acute myocardial infarction.
|
Blood Coagul Fibrinolysis
|
2005
|
0.75
|
|
194
|
Sex-associated differences in clinical outcomes after coronary stenting in patients with diabetes mellitus.
|
Am J Med
|
2004
|
0.75
|
|
195
|
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.
|
Eur Heart J
|
2020
|
0.75
|
|
196
|
Saphenous vein graft interventions.
|
Curr Treat Options Cardiovasc Med
|
2014
|
0.75
|
|
197
|
Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting.
|
Am Heart J
|
2011
|
0.75
|
|
198
|
Motivations for and barriers to choosing an interventional cardiology career path: results from the EAPCI Women Committee worldwide survey.
|
EuroIntervention
|
2016
|
0.75
|
|
199
|
Oxidized low density lipoproteins, statin therapy and severity of coronary artery disease.
|
Clin Chim Acta
|
2005
|
0.75
|
|
200
|
Sustained increased risk of adverse cardiac events over 5 years after implantation of gold-coated coronary stents.
|
Catheter Cardiovasc Interv
|
2006
|
0.75
|
|
201
|
Prognostic value of impaired fasting glucose for outcomes of patients with stable angina pectoris treated with percutaneous coronary interventions.
|
Am J Cardiol
|
2005
|
0.75
|
|
202
|
G protein beta 3 subunit 825T allele carriage and risk of coronary artery disease.
|
Atherosclerosis
|
2003
|
0.75
|
|
203
|
Glycoprotein VI polymorphisms and outcome after percutaneous coronary interventions.
|
Thromb Haemost
|
2007
|
0.75
|
|
204
|
ISAR--a story of trials with impact on practice.
|
Circ J
|
2010
|
0.75
|
|
205
|
Comparison of prognostic value of high-sensitivity and conventional troponin T in patients with non-ST-segment elevation acute coronary syndromes.
|
Clin Chim Acta
|
2011
|
0.75
|
|
206
|
PlA polymorphism of the glycoprotein IIIa and efficacy of reperfusion therapy in patients with acute myocardial infarction.
|
Thromb Haemost
|
2004
|
0.75
|